US · TLX · BIOTECHNOLOGY
Telix Pharmaceuticals Limited (TLX) intrinsic value and stock valuation
$8.37as of 2026-11-21 · Mkt cap 3.9B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Telix Pharmaceuticals Limited DCF and intrinsic value
InvestorsCraft values TLX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from TLX’s statements →
Telix Pharmaceuticals Limited Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 1999–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Praxis Precision Medicines, Inc. (PRAX) $300.43
- Mirum Pharmaceuticals, Inc. (MIRM) $96.13
- Belite Bio, Inc (BLTE) $127.38
- Ligand Pharmaceuticals Incorporated (LGND) $286.85
- ACADIA Pharmaceuticals Inc. (ACAD) $17.11
- Dyne Therapeutics, Inc. (DYN) $15.50
- Celcuity Inc. (CELC) $53.35
- Ultragenyx Pharmaceutical Inc. (RARE) $16.48
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.21B | $783.2M | $502.6M | $160.1M | $7.6M |
| Operating income | $26.6M | $82.1M | $15.8M | -$-91.93M | -$-81.25M |
| Net income | -$-10.69M | $49.9M | $5.21M | -$-104.08M | -$-80.51M |
| EPSd | -$-31.64K | $144.6K | $16.1K | -$-335.05K | -$-285.28K |
| Operating cash flow | -$-25.93M | $43M | $23.9M | -$-63.97M | -$-59.33M |
| Capital expenditure | -$-56.86M | -$-14.32M | -$-9.68M | -$-7.04M | -$-1.34M |
| Free cash flow | -$-82.8M | $28.7M | $14.2M | -$-71.01M | -$-60.67M |
| Total assets | $1.77B | $1.52B | $398.3M | $255.4M | $109.8M |
| Total debt | $699.8M | $581.5M | $17.5M | $10.5M | $2.54M |
| Net debt | $487.2M | -$-128.9M | -$-105.79M | -$-105.88M | -$-19.5M |
| Total equity | $622.3M | $568.2M | $148.9M | $80M | $2.16M |
| Cash and short-term investments | $212.5M | $710.4M | $123.2M | $116.3M | $22M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.21B | $783.2M | $502.6M | $160.1M | $7.6M |
| Cost of revenue | $565.2M | $273.5M | $188.2M | $65.2M | $38.7M |
| Gross profit | $640.2M | $509.7M | $314.4M | $94.9M | $5.05M |
| Research and development expenses | $256.8M | $121M | $128.8M | $57.9M | $34.1M |
| Selling, general and administrative expenses | $356.8M | $207.1M | $134.2M | $87.1M | $47M |
| Other expenses | $0.00 | $99.4M | $270K | $41.9M | -$-27.82M |
| Operating expenses | $613.6M | $427.6M | $263.3M | $186.9M | $53.3M |
| Cost and expenses | $1.18B | $701.1M | $486.7M | $252M | $92M |
| Interest income | $8.74M | $10.9M | $670K | $0.00 | $0.00 |
| Interest expense | $55.1M | $21.5M | $8.94M | $410K | $200K |
| Depreciation and amortization | $32.7M | $5.69M | $6.74M | $5.38M | $5.17M |
| Ebitda | $79.8M | $98.2M | $23M | -$-92.84M | -$-70.07M |
| Operating income | $26.6M | $82.1M | $15.8M | -$-91.93M | -$-81.25M |
| Total other income/expenses, net | -$-34.54M | -$-26.07M | -$-12.75M | -$-6.69M | -$-17.79M |
| Income before tax | -$-7.9M | $56.1M | $3.09M | -$-98.62M | -$-99.04M |
| Income tax expense | $2.79M | $6.14M | -$-2.07M | $5.46M | -$-18.53M |
| Net income | -$-10.69M | $49.9M | $5.21M | -$-104.08M | -$-80.51M |
| Weighted average shares outstanding | $337.9M | $331.2M | $319.2M | $310.6M | $282.2M |
| Weighted average diluted shares outstanding | $337.9M | $345.2M | $323.7M | $310.6M | $282.2M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $212.5M | $710.4M | $123.2M | $116.3M | $22M |
| Net receivables | $207.3M | $159M | $79.5M | $31.1M | $20.8M |
| Inventory | $55.6M | $38.1M | $17.3M | $5.77M | $3.45M |
| Total current assets | $494.8M | $918.6M | $224.9M | $173.2M | $47.5M |
| Property, plant and equipment, net | $173.2M | $54.3M | $30.5M | $18.8M | $6.33M |
| Goodwill and intangible assets | $888.1M | $416.1M | $109.7M | $64.5M | $59.8M |
| Long-term investments | $55.6M | $6.09M | $12.3M | -$-5.52M | $0.00 |
| Total non-current assets | $1.28B | $597.9M | $173.5M | $87.4M | $62.3M |
| Total assets | $1.77B | $1.52B | $398.3M | $255.4M | $109.8M |
| Accounts payable | $107.4M | $68.7M | $32.8M | $16.8M | $11.9M |
| Short-term debt | $28M | $21.5M | $1.56M | $1.28M | $630K |
| Deferred revenue | $17.2M | $11.3M | $11M | $4.94M | $6.14M |
| Total current liabilities | $347M | $330.9M | $157.4M | $85.6M | $38M |
| Long-term debt | $671.8M | $560M | $15.9M | $9.8M | $1.91M |
| Deferred revenue, non-current | $0.00 | $3.29M | $12.2M | $22.5M | $23.1M |
| Total non-current liabilities | $801.6M | $617.3M | $92M | $89.8M | $68.2M |
| Capital lease obligations | $93M | $10.6M | $8.27M | $7.13M | $2.52M |
| Total liabilities | $1.15B | $948.2M | $249.4M | $175.4M | $106.2M |
| Common stock | $719M | $596.8M | $446.3M | $371M | $170.8M |
| Retained earnings | -$-231.51M | -$-212.96M | -$-263.67M | -$-272.81M | -$-173.47M |
| Accumulated other comprehensive income (loss) | $134.8M | $184.4M | -$-33.69M | -$-18.15M | $4.79M |
| Total equity | $622.3M | $568.2M | $148.9M | $80M | $2.16M |
| Total investments | $55.6M | $6.09M | $12.3M | -$-5.52M | $0.00 |
| Total debt | $699.8M | $581.5M | $17.5M | $10.5M | $2.54M |
| Net debt | $487.2M | -$-128.9M | -$-105.79M | -$-105.88M | -$-19.5M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-10.69M | $49.9M | $5.21M | -$-104.08M | -$-80.51M |
| Depreciation and amortization | $32.7M | $8.02M | $6.74M | $5.38M | $5.17M |
| Stock-based compensation | $0.00 | $19.7M | $8.79M | $8.11M | $1.32M |
| Change in working capital | -$-67.81M | -$-98.82M | -$-57.53M | -$-28.64M | -$-7.42M |
| Accounts receivable | -$-30.69M | -$-57.08M | -$-27.38M | -$-19.93M | -$-7.19M |
| Inventory | -$-11.46M | -$-3.24M | -$-9.64M | -$-5.02M | -$-2.82M |
| Accounts payable | $43.5M | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash provided by operating activities | -$-25.93M | $43M | $23.9M | -$-63.97M | -$-59.33M |
| Investments in property, plant and equipment | -$-83.98M | -$-14.32M | -$-9.68M | -$-7.04M | -$-1.34M |
| Acquisitions, net | -$-330.92M | -$-34.69M | -$-1.48M | -$-970K | $0.00 |
| Net cash used for investing activities | -$-428.79M | -$-135.17M | -$-25.49M | -$-17M | -$-2.73M |
| Common stock issued | $2.71M | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-5.58M | $638.9M | $10.2M | $175M | $2.85M |
| Net change in cash | -$-446.35M | $587.1M | $6.91M | $94.3M | -$-55.91M |
| Cash at end of period | $212.5M | $710.4M | $123.2M | $116.3M | $22M |
| Operating cash flow | -$-25.93M | $43M | $23.9M | -$-63.97M | -$-59.33M |
| Capital expenditure | -$-56.86M | -$-14.32M | -$-9.68M | -$-7.04M | -$-1.34M |
| Free cash flow | -$-82.8M | $28.7M | $14.2M | -$-71.01M | -$-60.67M |
Line items
Line items
Line items
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
- CEO
- Christian Behrenbruch
- Employees
- 1.15K
- Beta
- 0.63
Explore
Frequently asked questions
What is the intrinsic value of Telix Pharmaceuticals Limited (TLX)?
Telix Pharmaceuticals Limited (TLX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is TLX undervalued?
TLX trades at a price of $8.37 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.